Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A US federal court has denied a motion by pharma companies Wyeth and Altana to block Teva Pharmaceutical from selling a generic version of its Protonix drug, a treatment for ulcers.
Subscribe to our email newsletter
The US district court in New Jersey denied the motion for a preliminary injunction by drugmakers Wyeth and Altana who were aiming to stop Israel-based Teva from launching generic versions of Protonix.
Teva has a 180-day period of marketing exclusivity, which will begin to run from the date of first commercial marketing or a final court decision, CNN reported.
Teva and Sun Pharmaceutical Industries have challenged the patent for Protonix, which expires in 2010 in the US. A trial date has not been set.
In 2006, Protonix generated sales of $1.8 billion, making it Wyeth's third best-selling product.